Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,60
KB-2,67
PKN121,28121,5-3,67
Msft-2,77
Nokia6,3266,384-9,16
IBM0,25
Mercedes-Benz Group AG37,29537,49-1,69
PFE-0,51
21.11.2026 2:00:20
Indexy online
AD Index online
select
AD Index online
 

  • 20.11.2026
Molecular Sp ADS (NASDAQ Cons)
Závěr k 20.11.2026 Změna (%) Změna (USD) Objem obchodů (USD)
2,53 1,41 0,04 1 118
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiMolecular Partners AG (ADR)
TickerMOLN
Kmenové akcie:ADR
RICMOLN.O
ISIN-
Poslední známé roční výsledky31.12.2025
Poslední známé čtvrtletní výsledky30.06.2026
Počet zaměstnanců k 31.12.2025 149
Akcie v oběhu k 30.06.2026 38 305 237
MěnaCHF
Kontaktní informace
UliceWagistrasse 14
MěstoSCHLIEREN
PSČ8952
ZeměSwitzerland
Kontatní osoba 
Funkce kontaktní osoby 
Telefon41 447 557 700
Fax41447557707

Business Summary: Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Molecular Partners AG (ADR) revenues was not reported. Net loss decreased 28% to SF26.7M. Lower net loss reflects Research and development expenses decrease of 16% to SF19.1M (expense), Restructuring expenses decrease from SF2.6M (expense) to SF0K, Selling/General/Admin Expense decrease of 3% to SF8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -SF1 to -SF0.70402.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Research and Development in Biotechnology
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive Director, Member of the Management BoardPatrick Amstutz5131.10.201701.01.2006
Chief Operating Officer, Member of the Management BoardAlexander Zuercher5101.07.202201.07.2022
Executive Vice President - People and Community, Member of the Management BoardRenate Gloggner5601.07.202201.07.2022
Executive Vice President - Projects, Member of the Management BoardMichael Stumpp5401.07.202201.01.2006
Chief Scientific Officer, Member of the Management BoardMartin Steegmaier6101.10.202501.10.2025
Chief Medical Officer, Member of the Management BoardPhilippe Legenne61